-
-
Overview
-
Please contact us at for specific academic pricing.
Background
INCB28060, also known as Capmatinib and INC280, is a novel and ATP-competitive inhibitor of c-Met with IC50 of 0.13 nM.
c-Met, also named as hepatocyte growth factor receptor (HGFR) is a receptor tyrosine kinase that is essential for embryonic development and would healing. In many tumor cells, this molecular is overexpressed or mutated and was found to play important roles in tumor cell proliferation, survival, invasion, metastasis and angiogenesis.
In vitro, INCB28060 treatment effectively inhibited activation of c-MET and signaling in cancer cells. As a result, INCB28060 blocked cell proliferation of varying cell lines such as SNU-5 and S114. The cell migration of U-87MG and H441 cells were also highly inhibited1.
The role of c-met was studied using this inhibitor in mouse model. Oral administration of INCB28060 leads to inhibition of c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models. Therefore, INCB28060 has the therapeutic potential in cancer treatment 1.
-
- Properties
-
Overview
- Home
- Products
- Life Science
- Analytical Chromatography
- Antibodies
- Assay Kits
- Antigens
- Biochemical Reagents
- Biospecimens
- Cell Culture
- Cell Analysis
- Chemicals
- Cloning and Expression
- Collagen
- Nucleic Acid Detection
- Nucleic Acid Extraction
- Enzymes
- Glycan Analysis
- Hydrogels
- Immunohistochemistry (IHC)
- Ion Exchange Resins
- Liposomes
- Microbiology
- Nanoparticles
- Nucleic Acid Electrophoresis
- Nucleic Acid Synthesis
- PCR
- Proteins
- Protein Biochemistry
- Protein Gel Electrophoresis
- Transfection Reagents
- Ubiquitin-Proteasome
- Venoms
- Lab Solutions
- Amerigo Scientific Instrument
- 3D Bioprinting
- Medical Devices
- Life Science
- Services
- About Us
- Contact Us
.
